Business Description
Cara Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US1407551092
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 16.55 | |||||
Equity-to-Asset | 0.45 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -9.36 | |||||
Beneish M-Score | -3.69 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -48.4 | |||||
3-Year FCF Growth Rate | -142.7 | |||||
3-Year Book Growth Rate | -40.6 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.62 | |||||
9-Day RSI | 46.15 | |||||
14-Day RSI | 45.37 | |||||
6-1 Month Momentum % | -32.44 | |||||
12-1 Month Momentum % | -79.88 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.54 | |||||
Quick Ratio | 4.43 | |||||
Cash Ratio | 3.94 | |||||
Days Inventory | 182.15 | |||||
Days Sales Outstanding | 89.01 | |||||
Days Payable | 540.48 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3 | |||||
Shareholder Yield % | -3.58 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 70.56 | |||||
Operating Margin % | -579.43 | |||||
Net Margin % | -565.21 | |||||
FCF Margin % | -439.31 | |||||
ROE % | -108.32 | |||||
ROA % | -83.33 | |||||
ROIC % | -587.15 | |||||
ROC (Joel Greenblatt) % | -1531.8 | |||||
ROCE % | -98.75 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.81 | |||||
PB Ratio | 0.67 | |||||
Price-to-Tangible-Book | 0.74 | |||||
EV-to-EBIT | 0.49 | |||||
EV-to-EBITDA | 0.49 | |||||
EV-to-Forward-EBITDA | -0.04 | |||||
EV-to-Revenue | -2.72 | |||||
EV-to-Forward-Revenue | 0.06 | |||||
EV-to-FCF | 0.61 | |||||
Price-to-Median-PS-Value | 0.06 | |||||
Price-to-Net-Current-Asset-Value | 0.9 | |||||
Price-to-Net-Cash | 1.31 | |||||
Earnings Yield (Greenblatt) % | 205.75 | |||||
FCF Yield % | -246.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cara Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 19.471 | ||
EPS (TTM) (€) | -2.03 | ||
Beta | 1.01 | ||
Volatility % | 85.04 | ||
14-Day RSI | 45.37 | ||
14-Day ATR (€) | 0.046991 | ||
20-Day SMA (€) | 0.706925 | ||
12-1 Month Momentum % | -79.88 | ||
52-Week Range (€) | 0.4742 - 4.044 | ||
Shares Outstanding (Mil) | 54.67 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cara Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cara Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Cara Therapeutics Inc Frequently Asked Questions
What is Cara Therapeutics Inc(STU:69C)'s stock price today?
When is next earnings date of Cara Therapeutics Inc(STU:69C)?
Does Cara Therapeutics Inc(STU:69C) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |